- Home
- RGTI vs PTGX Comparison
RGTI vs PTGX Comparison
Compare RGTI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGTI | PTGX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | 164 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.4B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | RGTI | PTGX |
|---|---|---|
| Price | $20.53 | $97.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $30.78 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 51.1M | 462.9K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | N/A |
| Revenue This Year | $225.06 | $874.25 |
| Revenue Next Year | $99.56 | N/A |
| P/E Ratio | ★ N/A | $2,055.80 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.01 | $49.86 |
| 52 Week High | $58.15 | $107.84 |
Technical Indicators
Market Signals| Indicator | RGTI | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 46.94 | 47.17 |
| Support Level | $14.51 | $96.36 |
| Resistance Level | $27.16 | $104.85 |
| Average True Range (ATR) | 2.64 | 4.25 |
| MACD | -0.15 | -0.26 |
| Stochastic Oscillator | 37.66 | 42.59 |
Price Performance
Historical ComparisonAbout RGTI Rigetti Computing Inc.
Rigetti Computing Inc builds quantum computers and the superconducting quantum processors that power them. The Company sells 9-qubit to 108-qubit quantum computing systems under the Novera and Cepheus trade names. Through the Rigetti Quantum Cloud Services (QCS) platform, the Company's machines can be integrated into any public, private or hybrid cloud. The Company also operates in Fremont, California; London, United Kingdom; Adelaide, Australia; British Columbia, Canada and Mumbai, India. The Company's revenue is derived from operations in the United States and the United Kingdom.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.